Clinical Trial Opportunity for Newly Diagnosed (Non Metastatic) Kidney Cancer

Guest Blog by Deb Maskens, Kidney Cancer Patient and Patient Advocate

Deb Maskens

As a community of kidney cancer patients, we often hear from patients who are newly diagnosed and looking for treatment options. This summary is written for those patients, and for patient advocates who help patients navigate through their treatment decisions.

Here’s the challenge: this clinical trial opportunity is available at many locations across the U.S. and Canada, but patients must ask about it BEFORE they undergo a nephrectomy. Their own doctors may well need to learn of the trial and to cooperate with the trial centres. The challenge in many places is that patients get booked for surgery prior to learning about this option. That would be too late for a trial like this–one that gives a drug therapy before the surgery for a brief period.

Why Might Patients Want to Consider this Trial?

For years, the standard of care for early stage kidney cancer has been to remove the tumour surgically, sometimes with the entire kidney–either a partial or full nephrectomy. That was the end of treatment and the beginning of surveillance to watch for any signs of recurrence.

More recently, there has been a drive to do better – to prevent a recurrence of disease. Since advanced or metastatic kidney cancer is still incurable for the vast majority of patients, this is a worthy goal. With preventive or ‘adjuvant’ treatments, maybe we can stop the disease before it gets to the lungs, liver, bones — to those places where it begins to threaten our lives. These types of treatments exist for other cancers and offer patients a real chance to avoid recurrence.

Adjuvant – and Perhaps One Step Better to Neo-Adjuvant

We’ve seen trials for “Adjuvant” therapy which hope to prevent recurrence (treatments given immediately after nephrectomy). And there is one trial that goes even one step better – it’s for “Neo-Adjuvant” (before nephrectomy) as well as Adjuvant (after).

Patients may want to rush to surgery to “get it out”. But, in reality, those tumours have generally been slowly growing, undetected for many years. Kidney cancer surgery is rarely an emergency. There is usually time for a second opinion and to check out any newer approaches.

Here’s the thought: given that the tumour cells have gone undetected and tolerated by the immune system for so long, is there a way we can put those millions of cells to work to “show their calling cards” to our immune system before we take them out?

Combining Neo-Adjuvant and Adjuvant Treatment – PROSPER-RCC


The Phase 3 clinical trial called PROSPER-RCC (NCT03055013) is intended for patients whose tumors are 7cm (2 ¾”) and larger in size, but not spread beyond the kidney area. These patients are at greater risk of spread of the cancer than those with Stage I or with smaller tumors.

Based on earlier studies, nivolumab is now approved for advanced kidney cancer, so this is a trial to test whether there is a benefit when nivolumab is given immediately before and after a nephrectomy when tumor cells might have spread outside the kidney but are too small (microscopic) to see on scans.

The Rationale for PROSPER-RCC

Here’s what I’ve learned:

  • Checkpoint inhibitor treatments with PD-1 blocking drugs seem to work best when the immune system may be being turned off by this pathway. Cancer is deceptively clever and some tumours can express a protein, PD-L1. This protein can turn off our immune cell responses that recognize and fight the cancer. We’ve seen a hint of this recently with some positive data that indicates that these drugs work best in patients whose tumors were “PD-L1 positive”.
  • In theory, when the kidney tumour is still in place, there are millions of cancer cells. All of those tumour cells are sending off multiple negative signals to the immune system to stop it from working. However, if a checkpoint inhibitor was introduced and stopped those blocking signals, the immune system would have a big wake-up call – e.g., lots of targets with which to build an army of T cells. In theory, these newly educated T cells would later turn into memory cells.

    This is much like what happens when we are exposed to certain bacteria or viruses. Once we get exposed to the bug, we don’t usually get it again. Our immune cells have learned (“immunity”) how to kill it more quickly the next time before it turns into a full blown cold. Similarly, if these anti-RCC immune cells ever see one of these tumor cells anywhere in our bodies again, they would know to attack and kill them even if there is no drug in the patient and has not been for some time.

  • Surgery is still the main treatment needed to control early stage kidney cancer. But it will also remove the majority of targets (PD-L1) that the checkpoint drug uses to rev up the immune system. So it makes sense to give the checkpoint inhibitor before surgery to maximize/optimize the drug’s ability to wake up the immune system and build that T cell army.
  • So the surgery is important. But let’s assume a few cells might be still circulating and go undetected for some time until enough can cluster to show up on a scan as an enlarged lymph node or spot somewhere. A boost of the same checkpoint inhibitor right after the surgery could then be used to remind the immune system to continue to look for those cells and kill/eliminate them when they are small. In theory, the immune system will remember what the past “trouble” was: “hey, haven’t I seen you before?”

    From what I understand, this theory worked well in mice. The checkpoint inhibitors worked better if the primary tumour was there to help provide “a target” to activate the immune system first before the tumor was removed. While we’re not mice, this makes sense, no?

Trial Design:

PROSPER-RCC will place patients randomly into two groups:

  • Group One gets two infusions of nivolumab before surgery (at about 28 days and 14 days before surgery). Following that nephrectomy, the patient will receive more infusions of nivolumab. This is for 9 months post-surgery altogether, with 12 more doses.
  • Group Two gets the usual standard of care: upfront nephrectomy, partial or radical nephrectomy, and will be followed by close observation at an expert centre.

It is important to note that no patient on this trial receives any intravenous placebo. Each patient will have either the experimental treatment or the standard of care, all under close observation at the trial centre. This trial has been designed and discussed with patient advocates and is supported by the NCI.

For More Information

Lay description here – http://www.10forio.info/clinical-trials/prosper-rcc

For contact information at over 100 trial sites: https://clinicaltrials.gov/ct2/show/NCT03055013


Call the office of the Principal Investigator, Dr. Lauren Harshman, at: 617-632-2429

Note from Kidney Cancer Canada: there are no Canadian centres that are recruiting for this trial yet. Visit our clinical trials page on this link for updates.

Deb’s Disclaimer:
As a patient and advocate for kidney cancer patients, I have been delving into the world of clinical trials and trying to understand as much as I can. I’m not a scientist, but I am a patient with this disease, so I bring that lens, along with some abilities to translate science into understandable terms. As a volunteer, I have no financial interest in this trial or any specific medications. @DebMaskensKCC; dmaskens@rogers.com

Do NOT follow this link or you will be banned from the site!